Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet (NASDAQ:PODD – Get Free Report) had its target price upped by equities researchers at Wells Fargo & Company from $305 ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

On Thursday, Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. The automated insulin delivery ...

Insulet Corporation ended 2024 with strong momentum, driven by record revenues, robust gross margin expansion, and successful market penetration of Omnipod 5 in both type 1 and type 2 diabetes.

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect. Insulet beat analysts’ revenue expectations by 4.9% ...

Good afternoon ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode. Later we will ...

Investors eyeing a purchase of Insulet Corp (Symbol: PODD) shares, but tentative about paying the going market price of $286.60/share, might benefit from considering selling puts among the ...

How far off is Insulet Corporation (NASDAQ:PODD) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected ...